---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-009585"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:47:17.754738+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics appoints Ronald Martell as CEO effective March 15, 2022

## Summary
- Ronald Martell appointed President and CEO, effective March 15, 2022; William Lis transitions to non-executive Chairperson.
- Martell receives $675,000 annual salary, 50% bonus target, and option to purchase 4.5% of outstanding shares vesting over 4 years.
- Additional 'True-Up Option' for 1.0% of shares granted if Jasper closes equity financing ≥$50 million after start date.
- Martell brings 30+ years biotech experience including CEO roles at MorphImmune, Nuvelution, and Achieve Life Sciences.
- If terminated without cause or for good reason, Martell receives 18 months base salary subject to release.

## SEC filing metadata
- accession: 0001213900-22-009585
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/0001213900-22-009585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/ea156240-8k_jasperther.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-009585
- JSON: https://secwatch.observer/filing/0001213900-22-009585.json
- Plain text: https://secwatch.observer/filing/0001213900-22-009585.txt

## Key facts
- Executive change
  Ronald Martell was appointed as President and Chief Executive Officer at Jasper Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/0001213900-22-009585-index.htm
- Executive change
  William Lis changed role as non-executive Chairperson at Jasper Therapeutics, Inc..
  - Action: will become
  - Role: non-executive Chairperson
  source text: William Lis, who is serving as President, Chief Executive Officer and Executive Chairman of the Board, will become the non-executive Chairperson of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/0001213900-22-009585-index.htm
- Executive change
  Ronald Martell was appointed as Class III director at Jasper Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390022009585/0001213900-22-009585-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.